Bladder Cancer

Anus, Esophagus, Lip, Oral Cavity and Pharynx, Lung, Other Female Genital, Other Male Genital, Other Urinary, Phase I, Urinary BladderA Phase 1 Dose-Escalation and Expansion Study Evaluating the Safety, Efficacy, and Pharmacokinetics of EVOLVE104 in Subjects With Advanced Urothelial and Squamous Cell Carcinomas
Esophagus, Larynx, Lip, Oral Cavity and Pharynx, Lung, Other Urinary, Pancreas, Phase I, Urinary BladderA Phase 1 Open-label Study to Investigate PF-08046876 in Adult Participants With Advanced Solid Tumors
Colon, Liver, Lung, Other Skin, Other Urinary, Phase I, Rectum, Urinary BladderA Phase I/II, Open-label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-drug Conjugate) as a Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Urinary BladderA Phase II Study of Consolidative Local Therapy in Patients With Locally Advanced or Oligo-metastatic Urothelial Carcinoma (la/mUC) Following Treatment Response to Systemic Therapy With or Without Metastasis-directed RadiotherapyPrincipal Investigator: Fed Ghali
Prostate, Urinary BladderAn Open-label, Multicenter, Dose Escalation, and Dose Expansion Phase 1/2 Study With Peluntamig (PT217) Followed by a Key ChemotherapY and/or Checkpoint Inhibitor ComBination in Patients With NeuRoendocrIne Carcinomas That Are Known to be DLL3 expressinG CancErs (SKYBRIDGE)